Acute Chest Syndrome

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY ADDING ONE MORE INDICATION WITH LONG TERM PROTECTION MASITINIB IS IN PHASE 2 IN SICKLE CELL DISEASE Paris, October 28, 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e. a medical use patent) with its lead compound masitinib, based on preclinical data. This new European patent provides intellectual property protection for masitinib in this indication until November 2040. Professor Olivier Hermine, President of the AB Science Scientific Committee and member of the French Academy of Sciences and Head of Hematology Department at Necker Hospital commented: “Masitinib represents a promising novel strategy for treating sickle cell disease and its serious complication of acute chest syndrome, which can lead to the development of chronic lung disease and is a common cause of hospitalization or even death. There is an increasing need in sickle cell disease with several new drugs being retrieved from market for lack of efficacy or toxicity; however, unlike masitinib, none of these drugs target mast cells”. Sickle cell disease (SCD) is a group of inherited red blood cell disorders, with masitinib being developed to treat the severest forms of the disease, accounting for about 65% of SCD. Severe SCD represents a major public health challenge and leads to early death. Treatment for SCD can be curative based on gene therapy (targets the HbS mutation), however, such an option remains extremely limited due to scarcity of donors, unresolved safety challenges, and very high costs. Standard treatment for SCD includes ​​red blood cell transfusions and treatment with hydroxyurea to manage complications, but significant unmet need remains. Mast cells, a major target for masitinib, appear to play a critical role for the severe forms of SCD and its complications, such as vaso-occlusive crises (VOC), acute chest syndrome (ACS), and pain [1-2]. Masitinib has demonstrated survival benefit in an SCD mouse model: all control SCD mice experienced VOC and 83% died in the first 3 hours, whereas SCD mice pretreated with masitinib for 4 days, experienced no VOCs and no death. Furthermore, lung histology and immune immunohistochemistry showed that masitinib protects from acute lung injuries and mast cell infiltration in an SCD mouse model. Masitinib clinical development in SCD is being conducted as part of the SICKMAST collaborative program, funded with 9.2 million euros [3], which aims to demonstrate in a phase 2 clinical trial the efficacy of masitinib in the treatment of acute and chronic complications of SCD in patients identified based on biomarkers. The Assistance Publique-Hôpitaux de Paris (AP-HP) will be the promoter of these phase 2 studies. AB Science will mainly be involved in supplying masitinib and monitoring masitinib pharmacovigilance data. AB Science remains free to carry out, as it sees fit, any potential phase 3 development following the success of phase 2. Sickle cell disease Sickle cell disease (SCD) is an autosomal recessive disorder affecting millions of people worldwide. Although life expectancy has increased over the last 20 years, acute and chronic complications still result in comorbidities, high social burden and premature death at around 40 years. Approximately 1.1% of couples worldwide are at risk of having a child with a hemoglobin disorder (sickle cell disease or thalassemia), and 2.3 conceptions per 1,000 are affected by sickle cell disease. Estimates suggest that each year, around 300,000 children are born with sickle cell disease, and this number could reach 400,000 by 2050 [4]. Sickle cell disease affects over 100,000 children and adults in the United States. In France, approximately 26,000 patients are affected (50% children, 50% adults). Rationale for the use of masitinib in this indication Inflammation mediated by innate immune cells and promoting vaso-occlusion has recently been shown to play a major role in sickle cell disease. In particular, our clinical observations and experimental work in mice, have revealed the involvement of mast cells and basophils in complications associated with sickle cell disease: The degree of mast cell activation in patients with sickle cell disease may contribute to the heterogeneity of inflammation and chronic and acute complications.The potential role of basophils in sickle cell disease has not been studied, however, given their role in various diseases and their ability to release substance P and histamine, they could also play important roles in the pathophysiology of sickle cell disease. Masitinib is an inhibitor of KIT, LYN, and FYN, three major kinases involved in the activation of mast cells and basophils. Medical need The classic view of sickle cell disease pathophysiology involves polymerization of mutated hemoglobin (HbS) leading to red blood cell (RBC) sickling with subsequent hemolytic anemia, painful vaso-occlusive crisis (VOC) and acute chest syndrome (ACS). Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease. Allogeneic stem cell transplantation and gene therapy are available only for a minority of patients, are associated with toxicity and are very expensive, which limits their use. There is a significant medical need to prevent the acute and chronic complications of sickle cell disease. References [1] Allali S, Lionnet F, Mattioni S, et al. Br J Haematol. 2019;186(1):125-129. [2] Allali S, Maciel TT, Hermine O, de Montalembert M. Haematologica. 2020;105(2):273-283. [3] AB Science Press Release, 27th November 2023. https://www.ab-science.com/the-clinical-development-of-masitinib-in-sickle-cell-disease-is-among-the-19-winning-projects-under-the-sixth-call-for-hospital-inuversity-research-in-health-rhu/ [4] Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561-1573. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: www.ab-science.com. Forward-looking Statements - AB Science This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB Science Financial Communication & Media Relations investors@ab-science.com Attachment Sickle Cell Patent EPO vENG VF

ROCKVILLE, Md.--( BUSINESS WIRE )--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process. “We are committed to acting in the best interests of patients, employees and shareholders. Given our organization’s cash resources, we plan to explore a range of potential strategic alternatives and seek to deliver value to our shareholders and find avenues that allow uproleselan and GMI-1687 to build upon their clinical promise, including in the ongoing NCI Phase 2/3 study of uproleselan in newly diagnosed AML patients,” said Harout Semerjian, Chief Executive Officer of GlycoMimetics. “We believe both drug candidates have the potential to address significant unmet needs in their respective therapeutic areas and we are focused on finding organizations to advance these programs. We are proud of our team’s dedication to improving the lives of patients and are thankful for their hard work progressing uproleselan and GMI-1687.” The Company will evaluate strategic alternatives and no timetable has been set for the conclusion of the strategic review or the consummation of any such strategic transaction. GlycoMimetics had cash and cash equivalents of approximately $31.3 million as of March 31, 2024. Based on the corporate restructuring and streamlining of operations, the Company expects to significantly reduce future operating expenses and extend its cash runway into the second quarter of 2025. NCI Phase 2/3 Study of Uproleselan in Frontline AML The National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology are conducting an adaptive Phase 2/3 study of uproleselan in adults with newly diagnosed AML who are 60 years or older and fit for intensive chemotherapy. Their randomized, controlled study is evaluating the addition of uproleselan to a standard cytarabine / daunorubicin regimen (7+3) versus chemotherapy alone. The Phase 2 portion of the study completed enrollment of 267 patients in December 2021. About AML AML is the most common acute leukemia in adults. A cancer of the bone marrow, nearly 21,000 people in the United States are diagnosed with AML each year. Despite the availability of multiple treatments, disease prognosis is poor, and new treatment options are needed to improve outcomes. Newly diagnosed AML has the lowest 5-year survival rate of all leukemias at 31.7%. The five-year survival rate for people with relapsed/refractory disease is only 10%. About Uproleselan Discovered and developed by GlycoMimetics, uproleselan (yoo’ pro le’se lan) is an investigational, first-in-class E-selectin antagonist. GlycoMimetics has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA) and Breakthrough Therapy designation from the Chinese National Medical Products Administration for uproleselan as a potential treatment for adult AML patients with relapsed or refractory disease. E-selectin is a leukocyte adhesion molecule constitutively expressed on endothelial cells of the vasculature and bone marrow. In AML, there is evidence that E-selectin–ligand interaction between endothelial cells in the protective niche of the Bone Marrow microEnvironment (BME) and leukemic stem cells and blasts promotes leukemic cell survival and hides them from AML therapies. Uproleselan is designed to disrupt E-selectin binding and prevent leukemic myeloid cells using the protective niche of the BME. About GMI-1687 Discovered and developed by GlycoMimetics, GMI-1687 is a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. This second-generation compound has potential application in oncology and inflammatory diseases, and the company’s initial clinical development has focused on sickle-cell disease (SCD). E-selectin is believed to play a major role in vaso-occlusive events (VOEs), a group of acute complications that are associated with SCD and include vaso-occlusive pain crises, acute chest syndrome (ACS), stroke, and splenic sequestration. Administration of GMI-1687 by subcutaneous injection, if successfully developed in the clinic, may enable this study drug to be approved as a patient-controlled, point-of-care treatment option. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com . Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of a strategic review of its business, the implementation of a corporate restructuring plan, the extension of its cash resources, and the potential benefits and impact of its product candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2024, the company’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

Businesses, Hospitals, Municipal Buildings, Museums, Schools, Landmarks To Illuminate In Red On World Sickle Cell Awareness Day To Show Support of Sickle Cell Warriors, Raise Awareness of Sickle Cell Disease, Advocate For A Universal Cure Fraternal Organization, Global Healthcare Company, NFL Team, Building Owners Management Association Join Campaign PHILADELPHIA, June 13, 2024 /PRNewswire/ -- A collaborative of 46 nonprofit, community-based organizations and medical providers in the Northeast U.S. is set to Shine the Light on Sickle Cell on June 19, World Sickle Cell Awareness Day. This collaborative initiative–which includes the illumination in red of businesses, hospitals, municipal buildings, museums, schools, and other landmarks–aims to unite individuals and communities in support of sickle cell warriors, raise awareness of Sickle Cell Disease (SCD) and advocate for a universal cure. Fraternal organization Phi Beta Sigma Fraternity, Inc., global healthcare company Novo Nordisk Inc., the Baltimore Ravens, and Building Owners Management Association-Philadelphia will also join the campaign that is supported by the federal Health Resources and Services Administration (HRSA) as part of the Sickle Cell Disease Treatment Demonstration Project. "Now in its sixth year, Shine the Light on Sickle Cell is a powerful testament to what we can achieve when communities, healthcare providers, and advocates unite," said Johns Hopkins University School of Medicine Professor Dr. Rosalyn Stewart. "Our goal is to make Sickle Cell Disease as common a topic as COVID or HIV and to inspire action towards a future where Sickle Cell Disease is better understood, better treated, and ultimately cured." SCD is a genetic blood disorder that disproportionately affects individuals of African descent yet remains widely misunderstood and underrepresented in public discourse. With over 100,000 people in the U.S. affected by SCD and millions more carrying the Sickle Cell Trait, the need for improved access to care and research advancements is critical. Individuals living with SCD often face numerous health complications, including stroke, acute chest syndrome, and chronic organ damage, leading to a significantly reduced life expectancy compared to the general population and earning them the name of sickle cell warrior. Despite these challenges, there is currently no universal cure for SCD. "I am deeply committed to shining the light on sickle cell and advocating for better care of people with the disease, a disease that causes severe episodic and chronic pain. Those with sickle cell disease frequently report poor interpersonal treatment within health-care settings," said Dr. Sophie Lanzkron, Director of the Division of Hematology at Thomas Jefferson University. "Eliminating the discrimination in health-care settings is imperative as research has proven its correlation with greater pain severity, stress, depression, and sleep issues." Shine the Light on Sickle Cell primarily operates in the Northeast region, encompassing New England, the mid-Atlantic, Virginia, West Virginia, the U.S. Virgin Islands, and Puerto Rico. Shine the Light on Sickle Cell's hallmark is the illumination of landmark structures and buildings in red – the emblematic color of the blood cell associated with the genetic disorder and a symbol of the urgency, passion, and unwavering determination in the fight against this disease – in the U.S. and around the world on and around June 19. Major landmarks that will Shine the Light on Sickle Cell this year include the Franklin Institute, the Hospital of the University of Pennsylvania, and Boathouse Row (Philadelphia); Novo Nordisk headquarters (Plainsboro Township, New Jersey); the Baltimore Ravens' M&T Bank Stadium and the Johns Hopkins University Dome (Baltimore); the Rhode Island State House (Providence); and University of Maryland's Capital Region Medical Center, Bowie Health Center, and Laurel Medical Center (Washington, D.C. metropolitan area). Zemoria Brandon is a longtime sickle cell advocate whose husband passed away from the disease in 1998. Now in her role as chair of the Shine the Light on Sickle Cell Steering Committee and administrator/social worker with Sickle Cell Disease Association of America, Philadelphia/Delaware Valley Chapter, Ms. Brandon said: "By illuminating our communities in red, we are symbolizing the urgency and passion needed to address the challenges of Sickle Cell Disease. Although Shine the Light on Sickle Cell began six years ago as an initiative in the Northeastern United States, it grew into a campaign, and now it has become a movement. It is uplifting to have seen participation from 29 states across the country and 21 countries around the world." Organizations in the collaborative are set to engage their community in various activities, including sickle celebrations, candlelight vigils, blood drives, awareness walks, wearing red, posting photos and videos on social media, and more. Shine the Light on Sickle Cell events (click for details and registration information) include: A Juneteenth Blood Drive and marquee illumination hosted by the Sickle Cell Association of Delaware at Cornerstone Fellowship Baptist Church in Wilmington A World Sickle Cell Day Conference sponsored by the Sickle Cell Thalassemia Patients Network in New York to discuss National Heart, Lung, and Blood Institute guidelines and American Society of Hematology clinical guidelines A Sickle Cellabration hosted by the Sickle Cell Association of New Jersey as part of an Annual Juneteenth Block Party in New Jersey A dinner event hosted by the Anemia Falciforme Sickle Cell Disease Association in Puerto Rico A Shine the Light on Sickle Cell event hosted by the Sickle Cell Association (Norfolk) in conjunction with the Juneteenth United Parade on the Eastern Shore of Virginia Join the conversation about Shine the Light on Sickle Cell using #shinethelightonsicklecell2024. About Shine the Light on Sickle Cell Shine the Light on Sickle Cell is an annual community awareness campaign to celebrate World Sickle Cell Awareness Day on June 19 as proclaimed by the United Nations in 2008 and to advocate for a universal cure. Shine the Light on Sickle Cell is led by a collaborative of 46 nonprofit, community-based organizations and medical providers in the Northeast United States, SiNERGe (Sickle Cell Improvement in the Northeast Region through education), whose aim is to increase awareness of Sickle Cell Disease and advocate for treatments and better outcomes for individuals with the disease. Learn more at Shine the Light on Sickle Cell. Media Contact ShinePR for Shine the Light on Sickle Cell [email protected] Participating organizations and provider organizations include (by state): Connecticut Citizens for Quality Sickle Cell Care* University of Connecticut Delaware Christiana Care Sickle Cell Association of Delaware District of Columbia Faces of Our Children Sickle Cell Association of the National Capital Area Inc. Maine Maine Medical Center Maryland Adult and Pediatric to Adult Sickle Cell Clinic, Johns Hopkins University Armstead-Barnhill Foundation for Sickle Cell Anemia Association for the Prevention of Sickle Cell Anemia Inc., Harford and Cecil Counties and the Eastern Shore* Christopher Gipson Sickle Cell Moyamoya Foundation Eastern Shore of Maryland Sickle Cell Association Johns Hopkins University Maryland Sickle Cell Disease Association* Project Spirit Sickle Cell Sally's Sunshine Foundation Sickle Cell Coalition of Maryland William E. Proudford Sickle Cell Fund Inc. Massachusetts Boston University Massachusetts General Hospital Massachusetts Sickle Cell Disease Association* New Hampshire Dartmouth Hitchcock Medical Center New Jersey Donna T. Darrien Memorial Foundation for Sickle Cell Newark Beth Israel Medical Center Sickle Cell Association of New Jersey*@ New York Candice's Sickle Cell Fund^ Children's Hospital of Monefiore New York Sickle Cell Advisory Network NYC Health + Hospitals New York Sickle Cell Advocacy Network (formerly Queens Sickle Cell Anemia Network)* Sickle Cell Advocates of Rochester^ Sickle Cell Awareness Foundation Corp International Sickle Cell Thalassemia Patients Network*@ Sickle Cell Warriors of Buffalo^ Westchester Sickle Cell Outreach Pennsylvania Children's Sickle Cell Foundation Inc.*#@ Crescent Foundation@ Sickle Cell Disease Association of America, Philadelphia/Delaware Valley Chapter*#@ South Central Pennsylvania Sickle Cell Council*# Hospital of the University of Pennsylvania Puerto Rico Anemia Falciforme Sickle Cell Disease en Puerto Rico Rhode Island Rhode Island Hospital Vermont University of Vermont Virginia Life and Family Foundation Richmond (formerly Living with Sickle Cell RVA) Sickle Cell Association Inc.* West Virginia CAMC Institute for Academic Medicine *Chapters of the Sickle Cell Disease Association of America (SCDAA) #Members of the Pennsylvania Sickle Cell Disease Providers Network (PASCDPN) ^Affiliates of Sickle Cell Thalassemia Patients Network (SCTPN) @HRSA Newborn Screening Grantees SOURCE Shine the Light on Sickle Cell